News
Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.
The TV personality, 71 - who once topped the scales at 237lbs in 1992 - finally reached her 160lb goal weight in 2023 after ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Insurance coverage for weight-loss drugs has recently increased, but typically only covers branded versions, according to ...
The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.
No matter how much you love these speculative winners, you don’t have a gain until you actually ring the register.
Hims & Hers Health Inc. investors have sued the telehealth provider days after Novo Nordisk A/S announced it was ending the ...
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
StockStory.org on MSN18h
Why Is Hims & Hers Health (HIMS) Stock Soaring TodayWhat Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the ...
Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...
Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...
Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results